Posted on Mar 9, 2020

Healthcare Medical Pharmaceutical Directory

FDA APPROVES RECORDATI / NOVARTIS ISTURISA (osilodrostat) TO TREAT CUSHING'S DISEASE
Recordati (BIT: REC) has been issued FDA approval for Isturisa which they licensed from Novartis in 2019.

It enables Recordati to start recouping its investment and Isturisa further benefits as the FDA assigned it Orphan Drug status that establishes 7 years of market exclusivity.

Isturisa is indicated for the treatment of Cushing’s Disease. Cushing’s Disease is a rare condition in which a patient’s adrenal glands generate an excessive amount of cortisol. Cushing's disease is usually found in adults 30 to 50 years of age and is more prevalent in women.

Osilodrostat is a steroidogenesis inhibitor of 11-Beta-hydroxylase, an enzyme that catalyses the last step of cortisol synthesis in the adrenal cortex.

Isturisa is the first therapy that is FDA-approved that treats cortisol overproduction by blocking the 11-beta-hydroxylase enzyme that triggers it.

Study the details of this promising new therapy, read the story here:
Contact Us
Message sent. We'll get back to you soon.